McKesson (MCK): What to Expect from Q4 Fiscal 2026 Earnings
Key Takeaways
- Analysts expect Q4 fiscal 2026 EPS of approximately $11.56–$11.57, a 14% year-over-year increase.
- Consensus revenue estimate stands at $101.4 billion, reflecting 12% growth from last year.
- McKesson reaffirmed FY2026 adjusted EPS guidance of $38.80–$39.20, implying strong Q4 performance needed to meet the range.
- Recent quarters show consistent beats, with Q3 adjusted EPS of $9.34 topping estimates by 0.5% and revenue up 11% YoY.
- Focus on oncology, specialty distribution, and GLP-1 (glucagon-like peptide-1) drugs drives growth expectations.
- Stock up modestly YTD 2026 at around 2%, lagging S&P 500 amid broader market volatility.
Earnings Context and Why This Report Matters
As McKesson Corporation (MCK), a leading healthcare distributor, approaches the end of its fiscal 2026 (March 31), the Q4 earnings report on May 7, 2026, will close out a year of solid growth. The company has raised its adjusted EPS guidance three times this year, landing at $38.80–$39.20. From what I see, investors are paying close attention to how McKesson is handling the surge in GLP-1 demand and its push into oncology, all while navigating pharmaceutical distribution challenges like industry consolidation and reimbursement pressures. Strong results here could validate the company's strategy, especially in a sector commanding premium multiples. For those holding shares, the FY2027 outlook and updates on capital returns—$2.4 billion year-to-date in FY2026—will offer insight into ongoing momentum within a $400+ billion addressable market.
What Wall Street Expects for Q4
Analysts project Q4 revenue at $101.4 billion, a 12% increase from Q4 FY2025, driven by elevated prescription volumes, specialty drugs, and retail national accounts. The adjusted EPS consensus sits at $11.56–$11.57, marking a 14% year-over-year rise and aligning with guidance that suggests Q4 needs to come in near the high end of the full-year range. I'm keeping an eye on key metrics like U.S. Pharmaceutical segment growth (GLP-1 reached ~$14 billion in Q3, up 26%), Oncology & Multispecialty margins, and free cash flow following $2.1 billion in share repurchases year-to-date.
McKesson has topped EPS estimates in each of the last four quarters, most recently with Q3's $9.34 (versus $9.29 expected) on $106.2 billion in revenue, up 11% year-over-year. Historically, the stock's post-earnings moves have averaged 5–10%, with beats typically pushing it higher given its low-beta profile (0.35–0.42).
Market Reaction and Current Sentiment
Sentiment heading into Q4 remains cautiously optimistic, supported by the three FY2026 guidance increases and the Q3 beat. The stock climbed as much as 16% in the days following Q3, though it's only up around 2% year-to-date in 2026, trailing the S&P 500 amid healthcare sector rotation. Potential risks include reimbursement shifts, generic pricing dynamics, and the resolution of Rite Aid exposure. Analysts continue to rate it a Strong Buy, with price targets ranging from ~$970 to $1,100, suggesting more than 20% upside. Implied volatility points to about a 5% move around the earnings event.
AI Screener: My Go-To for Spotting Opportunities Like MCK
In my analysis, I often turn to Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of names based on technical patterns, fundamentals, trends, volatility, and AI signals—using customizable criteria like industry, market cap, indicators, price patterns, and performance metrics. This approach uncovers trade ideas, trending stocks, breakouts, and opportunities far more efficiently than manual scans. I've found it particularly useful for identifying names like MCK ahead of key events like earnings.
Looking Ahead: FY2027 Guidance and Factors to Watch
The FY2027 guidance McKesson provides after Q4 will be crucial, following 17–19% adjusted EPS growth for FY2026. One thing that stands out is the long-term target of 13–16% annual EPS CAGR, with a strong emphasis on oncology and biopharma services.
Key drivers include continued GLP-1 momentum (Q3: $14 billion, +26% YoY), specialty distribution to health systems, and integration from recent M&A like PRISM Vision and Core Ventures. Margin gains in these high-growth areas could help counter pressures in pharmaceutical wholesaling, such as generics or DIR fees.
Cash flow generation has been robust ($1.1 billion free cash flow in Q3), backing $2.4 billion in shareholder returns so far this year. I'll be watching for updates on dividend increases (most recent at $0.82 per share) and buybacks. Broader tailwinds and headwinds include U.S. drug pricing reforms, biosimilar adoption, and completed international divestitures like Norway, which further hone the U.S. focus.
In my view, McKesson's ability to execute across segments will shape its path in this resilient healthcare supply chain.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
MCK sees its Stochastic Oscillator recovers from oversold territory
On June 25, 2026, the Stochastic Oscillator for MCK moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 46 instances where the indicator left the oversold zone. In of the 46 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MCK advanced for three days, in of 385 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 345 cases where MCK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MCK as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (19.710). P/E Ratio (19.407) is within average values for comparable stocks, (42.348). Projected Growth (PEG Ratio) (1.454) is also within normal values, averaging (1.285). MCK has a moderately low Dividend Yield (0.004) as compared to the industry average of (0.007). P/S Ratio (0.229) is also within normal values, averaging (5.989).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MCK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a distributer of pharmaceuticals and provides healthcare software and health information technology services
Industry MedicalDistributors
Advertisement